-
公开(公告)号：EP2358665B1
公开(公告)日：2014-04-23
申请号：EP09768168.8
申请日：2009-11-10
申请人： SANOFI
发明人： GARCIA, Eric , HOFF, Christian
IPC分类号： C07C249/14 , C07C251/58 , C07C57/15
CPC分类号： C07C249/14 , C07B2200/07 , C07C51/412 , C07C57/15 , C07C251/58
-
2.发明授权
公开(公告)号：EP2331549B1
公开(公告)日：2014-10-22
申请号：EP09748389.5
申请日：2009-09-15
申请人： SANOFI
IPC分类号： C07D493/18 , C07H19/01
CPC分类号： C07H3/02 , C07D493/18
-
3.发明授权NOUVELLE FORME DE L'IRBESARTAN, PROCEDES POUR OBTENIR LADITE FORME ET COMPOSITIONS PHARMACEUTIQUES EN CONTENANT 无效厄贝沙坦的新形式，METHODS这种形式获得并含有YOU的药物组合物
公开(公告)号：EP1089994B1
公开(公告)日：2004-09-08
申请号：EP99923712.6
申请日：1999-06-10
申请人： SANOFI-SYNTHELABO
发明人： FRANC, Bruno , HOFF, Christian , KIANG, San , LINDRUD, Mark, D. , MONNIER, Olivier , WEI, Chenkou
IPC分类号： C07D403/10 , A61K31/415
CPC分类号： C07D403/10
摘要： The invention concerns irbesartan form A having a modified crystalline habit such that length/width ratio ranges between 1:1 and 10:1, preferably between 1:1 and 5:1 and a method for preparing said crystalline habit. The method is characterised in that it consists in either subjecting a crystalline suspension of irbesartan form A having acicular habit to at least a temperature oscillating step, or in subjecting a crystalline suspension of irbesartan form A having acicular habit to a mechanical shearing. The invention also concerns a pharmaceutical composition containing said irbesartan crystalline habit.
-
公开(公告)号：EP2358665A1
公开(公告)日：2011-08-24
申请号：EP09768168.8
申请日：2009-11-10
申请人： SANOFI
发明人： GARCIA, Eric , HOFF, Christian
IPC分类号： C07C249/14 , C07C251/58 , C07C57/15
CPC分类号： C07C249/14 , C07B2200/07 , C07C51/412 , C07C57/15 , C07C251/58
摘要： Method for preparing eplivanserin hemifumarate.
-
5.发明公开
公开(公告)号：EP2331549A1
公开(公告)日：2011-06-15
申请号：EP09748389.5
申请日：2009-09-15
申请人： Sanofi-Aventis
IPC分类号： C07D493/18 , C07H19/01
CPC分类号： C07H3/02 , C07D493/18
摘要： The invention relates to a method for preparing 1,6:2,3-dianhydro-â-D-mannopyranose and is characterized in that it includes a step of cyclizing the compound C, where R is an alkyl group and R' is an activating agent, in an alcohol/alcoholate mixture under anhydrous conditions.
-
6.发明授权NOUVELLE FORME DE L'IRBESARTAN, PROCEDES POUR OBTENIR LADITE FORME ET COMPOSITIONS PHARMACEUTIQUES EN CONTENANT 无效厄贝沙坦的新形式，METHODS这种形式获得并含有YOU的药物组合物
公开(公告)号：EP1089994B9
公开(公告)日：2008-08-27
申请号：EP99923712.6
申请日：1999-06-10
申请人： Sanofi-Aventis
发明人： FRANC, Bruno , HOFF, Christian , KIANG, San , LINDRUD, Mark, D. , MONNIER, Olivier , WEI, Chenkou
IPC分类号： C07D403/10 , A61K31/415
CPC分类号： C07D403/10
摘要： The invention concerns irbesartan form A having a modified crystalline habit such that length/width ratio ranges between 1:1 and 10:1, preferably between 1:1 and 5:1 and a method for preparing said crystalline habit. The method is characterised in that it consists in either subjecting a crystalline suspension of irbesartan form A having acicular habit to at least a temperature oscillating step, or in subjecting a crystalline suspension of irbesartan form A having acicular habit to a mechanical shearing. The invention also concerns a pharmaceutical composition containing said irbesartan crystalline habit.
-
7.发明公开NOUVELLE FORME DE L'IRBESARTAN, PROCEDES POUR OBTENIR LADITE FORME ET COMPOSITIONS PHARMACEUTIQUES EN CONTENANT 无效厄贝沙坦的新形式，METHODS这种形式获得并含有YOU的药物组合物
公开(公告)号：EP1089994A1
公开(公告)日：2001-04-11
申请号：EP99923712.6
申请日：1999-06-10
申请人： SANOFI-SYNTHELABO
发明人： FRANC, Bruno , HOFF, Christian , KIANG, San , LINDRUD, Mark, D. , MONNIER, Olivier , WEI, Chenkou
IPC分类号： C07D403/10 , A61K31/415
CPC分类号： C07D403/10
摘要： The invention concerns irbesartan form A having a modified crystalline habit such that length/width ratio ranges between 1:1 and 10:1, preferably between 1:1 and 5:1 and a method for preparing said crystalline habit. The method is characterised in that it consists in either subjecting a crystalline suspension of irbesartan form A having acicular habit to at least a temperature oscillating step, or in subjecting a crystalline suspension of irbesartan form A having acicular habit to a mechanical shearing. The invention also concerns a pharmaceutical composition containing said irbesartan crystalline habit.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.011 秒)
